Aurobindo Pharma’s 100% stepdown subsidiary, Eugia Steriles Private Limited, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its new injectable facility. The inspection, conducted from March 28 to April 5, 2024, at the Parawada Mandal facility in Anakapalli District, Andhra Pradesh, has now been successfully closed.
The approval marks a significant milestone for Eugia Steriles, enabling it to move forward with product approvals for the US market. This development is expected to strengthen Aurobindo Pharma’s injectable portfolio and global market presence.
